MA53862A - Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci - Google Patents
Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ciInfo
- Publication number
- MA53862A MA53862A MA053862A MA53862A MA53862A MA 53862 A MA53862 A MA 53862A MA 053862 A MA053862 A MA 053862A MA 53862 A MA53862 A MA 53862A MA 53862 A MA53862 A MA 53862A
- Authority
- MA
- Morocco
- Prior art keywords
- 15ralpha
- targetting
- same
- fusion proteins
- combination therapies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862744946P | 2018-10-12 | 2018-10-12 | |
US201862784334P | 2018-12-21 | 2018-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53862A true MA53862A (fr) | 2022-01-19 |
Family
ID=68393093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053862A MA53862A (fr) | 2018-10-12 | 2019-10-11 | Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci |
Country Status (17)
Country | Link |
---|---|
US (2) | US11377477B2 (fr) |
EP (1) | EP3864047A2 (fr) |
JP (1) | JP2022504550A (fr) |
KR (1) | KR20210091710A (fr) |
CN (1) | CN113423734A (fr) |
AU (1) | AU2019359475A1 (fr) |
BR (1) | BR112021006783A2 (fr) |
CA (1) | CA3116188A1 (fr) |
CL (1) | CL2021000873A1 (fr) |
CO (1) | CO2021006092A2 (fr) |
CR (1) | CR20210239A (fr) |
IL (1) | IL282223A (fr) |
MA (1) | MA53862A (fr) |
MX (1) | MX2021004059A (fr) |
PE (1) | PE20211055A1 (fr) |
PH (1) | PH12021550802A1 (fr) |
WO (1) | WO2020077276A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10550185B2 (en) | 2016-10-14 | 2020-02-04 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments |
KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質 |
PE20211055A1 (es) | 2018-10-12 | 2021-06-07 | Xencor Inc | Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas |
US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
WO2022140797A1 (fr) * | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines et utilisations associées |
US20220227867A1 (en) * | 2020-12-24 | 2022-07-21 | Xencor, Inc. | ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS |
CN112851809A (zh) * | 2021-01-20 | 2021-05-28 | 上海交通大学 | 一种抗终末糖基化蛋白受体的抗体及其应用 |
KR20230148169A (ko) * | 2021-01-22 | 2023-10-24 | 엘피스 바이오파마슈티컬즈 | 항-pd-l1 모노클로날 항체 및 인터루킨-15 (il-15), 인터루킨-15 수용체 15 알파 또는 인터루킨-2와의 융합 단백질 |
TW202246357A (zh) * | 2021-03-09 | 2022-12-01 | 加拿大商康爾義明生物製藥公司 | 雙功能同源二聚體抗PD-1及IL-15/IL-15Rα融合蛋白及其用途 |
IL309533A (en) * | 2021-06-23 | 2024-02-01 | Cytune Pharma | Interleukin-15-based immunocytokines |
CN116023503B (zh) * | 2021-10-25 | 2024-05-31 | 上海交通大学 | 一种融合蛋白及其制备方法和用途 |
WO2023133424A2 (fr) * | 2022-01-05 | 2023-07-13 | TCR2 Therapeutics Inc. | Compositions et mé de reprogrammation de tcr à l'aide de protéines de fusion et de peptides de fusion anti-pd-1 |
CN115806628A (zh) * | 2022-08-03 | 2023-03-17 | 深圳市先康达生命科学有限公司 | 一种自分泌IL-15与anti-TIGIT结合的融合蛋白及其应用 |
CN117986383A (zh) * | 2022-11-02 | 2024-05-07 | 北京昌平实验室 | 融合蛋白及其应用 |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6451308B1 (en) | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
ES2243995T3 (es) | 1996-04-26 | 2005-12-01 | Beth Israel Deaconess Medical Center, Inc. | Antagonistas de interleucina-15. |
WO1998048032A2 (fr) | 1997-04-21 | 1998-10-29 | Donlar Corporation | ACIDE POLY-α-L-ASPARTIQUE, ACIDE-POLY-α-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION |
CA2352783C (fr) | 1998-12-03 | 2012-04-10 | The Regents Of The University Of California | Stimulation de lymphocytes t contre des auto-antigenes au moyen d'agents bloquants ctla-4 |
GEP20053594B (en) | 1998-12-23 | 2005-08-10 | Pfizer | Human Monoclonal Antibodies to CTLA-4 |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
RU2263118C2 (ru) | 1999-08-09 | 2005-10-27 | Лексиген Фармасьютикэлс Корп. | Комплексы антител с несколькими цитокинами |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
JP2005512044A (ja) | 2001-12-03 | 2005-04-28 | アブジェニックス・インコーポレーテッド | 結合特性に基づく抗体分類 |
WO2003073238A2 (fr) | 2002-02-27 | 2003-09-04 | California Institute Of Technology | Procede informatique de conception d'enzymes pour l'incorporation d'analogues d'acides amines dans des proteines |
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2368578A1 (fr) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés |
DK1944318T3 (da) | 2003-07-21 | 2011-06-14 | Transgene Sa | Multifunktionelle cytokiner |
EP2322569B1 (fr) | 2003-10-09 | 2020-08-26 | Ambrx, Inc. | Dérivés de polymère pour la modification selective de proteines |
WO2005056759A2 (fr) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Procedes pour produire des proteines variantes presentant une plus grande concentration en chaine hote et compositions de celles-ci |
US8778880B2 (en) | 2004-02-02 | 2014-07-15 | Ambrx, Inc. | Human growth hormone modified at position 35 |
JP5744369B2 (ja) | 2004-02-27 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | IL15−Rα用IL−15結合部位およびアゴニスト/アンタゴニスト活性を有する特異的IL−15突然変異体 |
CA2561264A1 (fr) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Variantes d'immunoglobuline a l'exterieur de la region fc |
CU23472A1 (es) | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la interleucina-15 |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
WO2006063974A2 (fr) | 2004-12-13 | 2006-06-22 | Cytos Biotechnology Ag | Jeux ordonnes d'antigenes il-15 et leurs utilisations |
WO2006106905A1 (fr) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Procede pour la production de polypeptide au moyen de la regulation d’un ensemble |
US20060257361A1 (en) | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
CN105315373B (zh) | 2005-05-09 | 2018-11-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
AU2006262711B2 (en) | 2005-05-17 | 2013-01-31 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
WO2007005612A2 (fr) | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine |
PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
EP1777294A1 (fr) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion |
WO2007084342A2 (fr) | 2006-01-13 | 2007-07-26 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Il-15 et il-15r-alpha améliorées aux fins d'expression dans des cellules mammaliennes |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
ES2606490T3 (es) | 2006-05-08 | 2017-03-24 | Philogen S.P.A. | Citocinas dirigidas por anticuerpos para terapia |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP1987839A1 (fr) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes |
US8629245B2 (en) | 2007-05-01 | 2014-01-14 | Research Development Foundation | Immunoglobulin Fc libraries |
DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
EP2666787B1 (fr) | 2007-05-31 | 2022-02-09 | Genmab A/S | ANTICORPS IgG4 STABLES |
MX2009014199A (es) | 2007-06-18 | 2010-05-24 | Organon Nv | Anticuerpos para el receptor 1 de muerte programada pd-1 de humano. |
EP2724727A1 (fr) | 2007-06-27 | 2014-04-30 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Complexes d'alpha IL-15 et IL-15R et leurs utilisations |
MX2010002683A (es) | 2007-09-14 | 2010-03-26 | Amgen Inc | Poblaciones de anticuerpos homogeneos. |
ES2774337T3 (es) | 2008-01-07 | 2020-07-20 | Amgen Inc | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
WO2010017103A2 (fr) | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Anticorps monoclonaux anti-nkg2d humain entièrement humains |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP2927240A1 (fr) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions d'antagonistes pd-1 et procédés d'utilisation |
JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Pd−1アンタゴニストおよび感染性疾患を処置するための方法 |
KR101782570B1 (ko) | 2008-12-09 | 2017-09-27 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
US8057507B2 (en) | 2009-01-16 | 2011-11-15 | Novate Medical Limited | Vascular filter |
EP2233500A1 (fr) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Variantes Fc optimisées |
JP5683581B2 (ja) | 2009-06-30 | 2015-03-11 | リサーチ ディベロップメント ファウンデーション | 免疫グロブリンFcポリペプチド |
AU2010270844A1 (en) | 2009-07-08 | 2011-12-22 | Amgen Inc. | Design of stable and aggregation free antibody Fc molecules through CH3 domain interface engineering |
JP2013501817A (ja) | 2009-08-14 | 2013-01-17 | アメリカ合衆国 | 胸腺産出の増大およびリンパ球減少症の治療のためのil−15の使用 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2504360B1 (fr) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Anticorps monomère fc |
WO2011066342A2 (fr) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Inhibition simultanée de pd-l1/pd-l2 |
EP3279215B1 (fr) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Agents de liaison ciblés contre b7-h1 |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
KR102152109B1 (ko) | 2010-04-20 | 2020-09-07 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
EP3029066B1 (fr) | 2010-07-29 | 2019-02-20 | Xencor, Inc. | Anticorps à points isoélectriques modifiés |
WO2012032080A1 (fr) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Fc humain stabilisé |
EP3327040B1 (fr) | 2010-09-21 | 2021-06-23 | Altor BioScience Corporation | Molécules de fusion multimères solubles à base d'il-15, leurs procédés de préparation et d'utilisation |
PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
KR102108521B1 (ko) | 2011-03-25 | 2020-05-11 | 아이크노스 사이언스 에스. 아. | 헤테로 이량체 면역글로불린 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
EP2537933A1 (fr) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi |
TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
KR102143331B1 (ko) | 2011-09-30 | 2020-08-11 | 추가이 세이야쿠 가부시키가이샤 | 항원의 소실을 촉진시키는 항원 결합 분자 |
JP6310394B2 (ja) | 2011-10-10 | 2018-04-11 | ゼンコア インコーポレイテッド | 抗体を精製する方法 |
RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
AU2013211059B8 (en) | 2012-01-20 | 2017-12-21 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted mutant alpha-helical bundle cytokines |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
EP2922874A4 (fr) | 2012-11-21 | 2016-10-19 | Wuhan Yzy Biopharma Co Ltd | Anticorps bispécifiques |
KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
WO2014145907A1 (fr) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Ciblage des lymphocytes t avec des protéines hétérodimères |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
ES2885696T3 (es) | 2013-03-15 | 2021-12-15 | Xencor Inc | Proteínas heterodiméricas |
KR20150145260A (ko) | 2013-04-19 | 2015-12-29 | 싸이튠 파마 | 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료 |
JP6329343B2 (ja) | 2013-06-13 | 2018-05-23 | 任天堂株式会社 | 画像処理システム、画像処理装置、画像処理プログラム、および画像処理方法 |
EP3013356B1 (fr) | 2013-06-27 | 2018-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonistes d'interleukine 15 (il -15) et leurs utilisations pour le traitement de maladies auto-immunes et de maladies inflammatoires |
US10299875B2 (en) | 2013-07-19 | 2019-05-28 | Firefly Medical, Inc. | Devices for mobility assistance and infusion management |
EA031080B1 (ru) | 2013-08-08 | 2018-11-30 | Ситюн Фарма | МОДУЛОКИНЫ НА ОСНОВЕ ДОМЕНА SUSHI IL-15 И IL-15Rα |
PL3030262T3 (pl) | 2013-08-08 | 2020-07-27 | Cytune Pharma | Złożona kompozycja farmaceutyczna |
KR20160103058A (ko) | 2014-01-08 | 2016-08-31 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | Il-15 이종 이량체 단백질 및 그의 용도 |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
EP2915569A1 (fr) | 2014-03-03 | 2015-09-09 | Cytune Pharma | Procédé de purification de conjugués à base Il -15/IL-15Ralpha |
PE20170071A1 (es) | 2014-03-14 | 2017-03-17 | Novartis Ag | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas |
AP2016009475A0 (en) | 2014-03-28 | 2016-09-30 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
US20150351275A1 (en) | 2014-05-30 | 2015-12-03 | Johanson Manufacturing Corporation | Thin-Film Radio Frequency Power Terminator |
WO2015195163A1 (fr) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Anticorps totalement humain anti-pd-l1 |
CN113384686A (zh) | 2014-06-30 | 2021-09-14 | 阿尔托生物科学有限公司 | 基于il-15的分子及其方法和用途 |
BR112017000703A2 (pt) | 2014-07-16 | 2017-11-14 | Genentech Inc | métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit |
US9763705B2 (en) | 2014-10-03 | 2017-09-19 | Globus Medical, Inc. | Orthopedic stabilization devices and methods for installation thereof |
TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
EP3206713A4 (fr) | 2014-10-14 | 2018-06-27 | Armo Biosciences, Inc. | Compositions d'interleukine-15 et leurs utilisations |
RU2017119185A (ru) | 2014-11-05 | 2018-12-05 | Дженентек, Инк. | Антитела против fgfr2/3 и способы их применения |
US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3及びcd38に結合するヘテロ二量体抗体 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EP3928788A1 (fr) | 2014-11-26 | 2021-12-29 | Xencor, Inc. | Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20 |
JP6709456B2 (ja) | 2014-12-19 | 2020-06-17 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | インターロイキン15タンパク複合体およびそれらの用途 |
CA3175979A1 (fr) * | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anticorps anti-pd-1 |
CN107207594B (zh) | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
WO2016141387A1 (fr) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc |
EP3064507A1 (fr) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Protéines de fusion comprenant une protéine de liaison et un polypeptide interleukine-15 ayant une affinité réduite pour IL15ra et leurs utilisations thérapeutiques |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
CR20180225A (es) | 2015-09-25 | 2018-07-09 | Genentech Inc | Anticuerpo anti-tigit y métodos de uso |
AU2016326575A1 (en) | 2015-09-25 | 2018-04-12 | Altor Bioscience Corporation | Interleukin-15 superagonist significantly enhances graft-versus-tumor activity |
AU2016333517B2 (en) * | 2015-10-02 | 2023-09-07 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
EP3481799A1 (fr) | 2016-07-05 | 2019-05-15 | Novartis AG | Nouveau procédé pour des intermédiaires de sacubitril précoces |
US10550185B2 (en) | 2016-10-14 | 2020-02-04 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments |
BR112019007920A2 (pt) | 2016-10-21 | 2019-10-08 | Altor Bioscience Corp | moléculas multiméricas à base de il-15 |
WO2018091661A1 (fr) * | 2016-11-18 | 2018-05-24 | Symphogen A/S | Anticorps anti-pd-1 et compositions |
WO2019006472A1 (fr) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
WO2019157340A1 (fr) | 2018-02-08 | 2019-08-15 | Amgen Inc. | Formulation d'anticorps pharmaceutique à ph faible |
BR112020016859A2 (pt) | 2018-02-28 | 2020-12-29 | Pfizer Inc. | Variantes de il-15 e usos da mesma |
EP3781596A1 (fr) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations |
KR20210010862A (ko) * | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
PE20211055A1 (es) | 2018-10-12 | 2021-06-07 | Xencor Inc | Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas |
US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
-
2019
- 2019-10-11 PE PE2021000502A patent/PE20211055A1/es unknown
- 2019-10-11 WO PCT/US2019/055956 patent/WO2020077276A2/fr active Application Filing
- 2019-10-11 CR CR20210239A patent/CR20210239A/es unknown
- 2019-10-11 CA CA3116188A patent/CA3116188A1/fr active Pending
- 2019-10-11 AU AU2019359475A patent/AU2019359475A1/en not_active Abandoned
- 2019-10-11 US US16/600,236 patent/US11377477B2/en active Active
- 2019-10-11 KR KR1020217014323A patent/KR20210091710A/ko unknown
- 2019-10-11 BR BR112021006783-3A patent/BR112021006783A2/pt not_active Application Discontinuation
- 2019-10-11 MA MA053862A patent/MA53862A/fr unknown
- 2019-10-11 JP JP2021519617A patent/JP2022504550A/ja active Pending
- 2019-10-11 MX MX2021004059A patent/MX2021004059A/es unknown
- 2019-10-11 CN CN201980075190.4A patent/CN113423734A/zh active Pending
- 2019-10-11 EP EP19795737.6A patent/EP3864047A2/fr active Pending
-
2021
- 2021-04-09 CL CL2021000873A patent/CL2021000873A1/es unknown
- 2021-04-11 IL IL282223A patent/IL282223A/en unknown
- 2021-04-12 PH PH12021550802A patent/PH12021550802A1/en unknown
- 2021-05-11 CO CONC2021/0006092A patent/CO2021006092A2/es unknown
-
2022
- 2022-06-02 US US17/831,197 patent/US20230055445A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020077276A2 (fr) | 2020-04-16 |
PH12021550802A1 (en) | 2021-10-04 |
US20200140512A1 (en) | 2020-05-07 |
CA3116188A1 (fr) | 2020-04-16 |
CR20210239A (es) | 2021-12-15 |
US11377477B2 (en) | 2022-07-05 |
CO2021006092A2 (es) | 2021-08-09 |
EP3864047A2 (fr) | 2021-08-18 |
AU2019359475A1 (en) | 2021-05-20 |
PE20211055A1 (es) | 2021-06-07 |
MX2021004059A (es) | 2021-09-23 |
WO2020077276A3 (fr) | 2020-05-14 |
US20230055445A1 (en) | 2023-02-23 |
BR112021006783A2 (pt) | 2021-07-13 |
CL2021000873A1 (es) | 2021-12-10 |
KR20210091710A (ko) | 2021-07-22 |
CN113423734A (zh) | 2021-09-21 |
IL282223A (en) | 2021-05-31 |
JP2022504550A (ja) | 2022-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53862A (fr) | Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci | |
MA49514A (fr) | Particules virales recombinantes avec tropisme modifié, et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines | |
IL278091A (en) | Heterodimeric 1-PD-targeted OH-FC proteins containing OH-IL-15/IL-15Rα FC proteins and 1-PD antigen binding regions and uses thereof | |
MA49517A (fr) | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène | |
SA518391722B1 (ar) | أجسام مضادة تستهدف شبيه مستقبل Fc5 وطرق استخدامها | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
MA46290A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
MA51676A (fr) | Protéines de fusion il-22 fc et procédés d'utilisation | |
MA56165A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
IL280102A (en) | Fusion protein containing PD1-4-1BBL and methods of using it | |
DK4011908T3 (da) | Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf | |
MX2018003689A (es) | Proteinas de union a pd-1 y metodos para usarlas. | |
MA37945A1 (fr) | Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées | |
MA52910A (fr) | Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs | |
MA49727A (fr) | Anticorps et polypeptides dirigés contre cd127 | |
MA48462A (fr) | Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation | |
MA46111A (fr) | Bactéries génétiquement modifiées sécrétant des protéines thérapeutiques et procédés d'utilisation de celles-ci | |
MA53651A (fr) | Méthodes et utilisations de protéines de fusion de variant cd80 et constructions associées | |
IL280103A (en) | Fusion protein containing SIRPalpha-4-1BBL and methods of using it | |
EP3708661A4 (fr) | Protéine de fusion d'enzyme thérapeutique à nouvelle structure et son utilisation | |
IL271837B1 (en) | A new medical fusion protein with an enzyme and its uses | |
MX351841B (es) | Un conjunto de construcción de juguete. | |
EP3969125A4 (fr) | Utilisation d'anticorps anti-fcrn dans le traitement du pemphighus et de maladies du pemphigoïde | |
PH12017501914A1 (en) | Polypeptides targeting hiv fusion | |
MA52238A (fr) | Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées |